vs
Cardio Diagnostics Holdings, Inc.（CDIO）与Alpha Teknova, Inc.（TKNO）财务数据对比。点击上方公司名可切换其他公司
Alpha Teknova, Inc.的季度营收约是Cardio Diagnostics Holdings, Inc.的2808.4倍（$10.0M vs $3.6K）。Alpha Teknova, Inc.同比增速更快（7.8% vs -21.2%）。Alpha Teknova, Inc.自由现金流更多（$-810.0K vs $-5.9M）。过去两年Alpha Teknova, Inc.的营收复合增速更高（3.7% vs -52.8%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Alpha Teknova, Inc.是一家生命科学企业，研发并生产专用试剂、细胞培养基及定制实验室解决方案，服务生物制药、分子诊断及学术研究领域客户，主要面向北美市场，为药物研发、诊断测试及生命科学研究流程提供支持。
CDIO vs TKNO — 直观对比
营收规模更大
TKNO
是对方的2808.4倍
$3.6K
营收增速更快
TKNO
高出29.0%
-21.2%
自由现金流更多
TKNO
多$5.1M
$-5.9M
两年增速更快
TKNO
近两年复合增速
-52.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $10.0M |
| 净利润 | — | $-4.8M |
| 毛利率 | — | 32.5% |
| 营业利润率 | — | -46.2% |
| 净利率 | — | -47.7% |
| 营收同比 | -21.2% | 7.8% |
| 净利润同比 | 3.6% | 16.8% |
| 每股收益（稀释后） | — | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOTKNO
| Q4 25 | $3.6K | $10.0M | ||
| Q3 25 | $2.9K | $10.5M | ||
| Q2 25 | $7.5K | $10.3M | ||
| Q1 25 | $940 | $9.8M | ||
| Q4 24 | $4.5K | $9.3M | ||
| Q3 24 | $6.6K | $9.6M | ||
| Q2 24 | $7.9K | $9.6M | ||
| Q1 24 | $15.9K | $9.3M |
净利润CDIOTKNO
| Q4 25 | — | $-4.8M | ||
| Q3 25 | $-1.7M | $-4.3M | ||
| Q2 25 | $-1.7M | $-3.6M | ||
| Q1 25 | $-1.6M | $-4.6M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | $-1.4M | $-7.6M | ||
| Q2 24 | $-1.3M | $-5.4M | ||
| Q1 24 | $-4.2M | $-8.1M |
毛利率CDIOTKNO
| Q4 25 | — | 32.5% | ||
| Q3 25 | — | 30.7% | ||
| Q2 25 | — | 38.7% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 23.0% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 29.2% | ||
| Q1 24 | — | 23.8% |
营业利润率CDIOTKNO
| Q4 25 | — | -46.2% | ||
| Q3 25 | -59950.9% | -38.4% | ||
| Q2 25 | -22457.5% | -32.9% | ||
| Q1 25 | -173463.8% | -50.7% | ||
| Q4 24 | — | -60.7% | ||
| Q3 24 | -21412.9% | -77.6% | ||
| Q2 24 | -16295.6% | -53.0% | ||
| Q1 24 | -26105.3% | -86.0% |
净利率CDIOTKNO
| Q4 25 | — | -47.7% | ||
| Q3 25 | -60053.8% | -41.0% | ||
| Q2 25 | -22517.7% | -34.7% | ||
| Q1 25 | -173943.0% | -47.4% | ||
| Q4 24 | — | -61.7% | ||
| Q3 24 | -21467.6% | -79.0% | ||
| Q2 24 | -16365.9% | -55.8% | ||
| Q1 24 | -26140.0% | -87.2% |
每股收益（稀释后）CDIOTKNO
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.98 | $-0.08 | ||
| Q2 25 | $-0.97 | $-0.07 | ||
| Q1 25 | $-0.97 | $-0.09 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-1.73 | $-0.15 | ||
| Q2 24 | $-1.71 | $-0.13 | ||
| Q1 24 | $-5.93 | $-0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $21.3M |
| 总债务越低越好 | — | $13.1M |
| 股东权益账面价值 | $7.0M | $68.8M |
| 总资产 | $7.8M | $103.6M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资CDIOTKNO
| Q4 25 | — | $21.3M | ||
| Q3 25 | — | $22.1M | ||
| Q2 25 | — | $24.0M | ||
| Q1 25 | — | $26.3M | ||
| Q4 24 | — | $30.4M | ||
| Q3 24 | — | $31.7M | ||
| Q2 24 | — | $18.6M | ||
| Q1 24 | — | $21.6M |
总债务CDIOTKNO
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
股东权益CDIOTKNO
| Q4 25 | $7.0M | $68.8M | ||
| Q3 25 | $8.2M | $72.7M | ||
| Q2 25 | $9.7M | $76.1M | ||
| Q1 25 | $11.4M | $78.6M | ||
| Q4 24 | $9.6M | $82.4M | ||
| Q3 24 | $3.7M | $87.3M | ||
| Q2 24 | $3.1M | $78.9M | ||
| Q1 24 | $3.0M | $83.4M |
总资产CDIOTKNO
| Q4 25 | $7.8M | $103.6M | ||
| Q3 25 | $8.8M | $107.6M | ||
| Q2 25 | $10.4M | $110.5M | ||
| Q1 25 | $12.3M | $114.0M | ||
| Q4 24 | $10.6M | $118.8M | ||
| Q3 24 | $4.5M | $124.1M | ||
| Q2 24 | $4.0M | $115.4M | ||
| Q1 24 | $4.3M | $120.8M |
负债/权益比CDIOTKNO
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-462.0K |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-810.0K |
| 自由现金流率自由现金流/营收 | -166361.5% | -8.1% |
| 资本支出强度资本支出/营收 | 5269.1% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-10.5M | $-9.8M |
8季度趋势，按日历期对齐
经营现金流CDIOTKNO
| Q4 25 | $-5.7M | $-462.0K | ||
| Q3 25 | $-1.4M | $-2.0M | ||
| Q2 25 | $-1.6M | $-2.1M | ||
| Q1 25 | $-1.4M | $-4.1M | ||
| Q4 24 | $-5.0M | $-936.0K | ||
| Q3 24 | $-1.2M | $-2.1M | ||
| Q2 24 | $-1.2M | $-2.8M | ||
| Q1 24 | $-1.2M | $-6.6M |
自由现金流CDIOTKNO
| Q4 25 | $-5.9M | $-810.0K | ||
| Q3 25 | $-1.6M | $-2.4M | ||
| Q2 25 | $-1.6M | $-2.3M | ||
| Q1 25 | $-1.4M | $-4.3M | ||
| Q4 24 | $-5.2M | $-1.5M | ||
| Q3 24 | $-1.2M | $-2.4M | ||
| Q2 24 | $-1.4M | $-3.0M | ||
| Q1 24 | $-1.3M | $-6.7M |
自由现金流率CDIOTKNO
| Q4 25 | -166361.5% | -8.1% | ||
| Q3 25 | -54509.7% | -22.6% | ||
| Q2 25 | -21273.1% | -22.4% | ||
| Q1 25 | -149562.6% | -44.0% | ||
| Q4 24 | -115422.6% | -16.2% | ||
| Q3 24 | -17942.3% | -25.0% | ||
| Q2 24 | -17513.3% | -30.7% | ||
| Q1 24 | -7866.9% | -71.8% |
资本支出强度CDIOTKNO
| Q4 25 | 5269.1% | 3.5% | ||
| Q3 25 | 5703.5% | 3.7% | ||
| Q2 25 | 250.1% | 2.0% | ||
| Q1 25 | 615.6% | 2.1% | ||
| Q4 24 | 4759.9% | 6.1% | ||
| Q3 24 | 353.3% | 3.5% | ||
| Q2 24 | 2133.4% | 1.2% | ||
| Q1 24 | 125.5% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDIO
暂无分部数据
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
